Casper W.F. van Eijck

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Casper H.J. van Eijck · 14 shared papers, 2023–2026 · strength 3.12
   • Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
   • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
   • Paper Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. DOI 10.1016/j.hpb.2025.02.002↗
2. Dana A. M. Mustafa · 8 shared papers, 2023–2024 · strength 1.67
   • Paper A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FO… DOI 10.1016/j.neo.2024.100975↗
   • Paper GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoin… DOI 10.1016/j.xcrm.2024.101557↗
   • Paper Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with rese… DOI 10.1136/gutjnl-2023-330480↗
3. Judith de Vos‐Geelen · 4 shared papers, 2025–2026 · strength 1.10
   • Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
   • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
   • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
4. Aniek E. van Diepen · 4 shared papers, 2025–2026 · strength 1.10
   • Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
   • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
   • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
5. Núria Malats Riera · 5 shared papers, 2024–2025 · strength 1.08
   • Paper A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FO… DOI 10.1016/j.neo.2024.100975↗
   • Paper GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoin… DOI 10.1016/j.xcrm.2024.101557↗
   • Paper A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational stud… DOI 10.1136/gutjnl-2024-334237↗
6. Marjolein Y.V. Homs · 4 shared papers, 2023–2026 · strength 0.93
   • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
   • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
   • Paper A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with panc… DOI 10.1016/j.ejca.2022.12.024↗
7. Gaby J. Strijk · 4 shared papers, 2023–2026 · strength 0.92
   • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
   • Paper A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FO… DOI 10.1016/j.neo.2024.100975↗
   • Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
8. Bas Groot Koerkamp · 4 shared papers, 2023–2024 · strength 0.81
   • Paper A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FO… DOI 10.1016/j.neo.2024.100975↗
   • Paper Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with rese… DOI 10.1136/gutjnl-2023-330480↗
   • Paper A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with panc… DOI 10.1016/j.ejca.2022.12.024↗
9. Songul Kucukcelebi · 3 shared papers, 2024–2026 · strength 0.76
   • Paper CD40 Agonism in Pancreatic Ductal Adenocarcinoma: Expression, Biology, and Therapeutic Targeting. DOI 10.3390/cancers18111743↗
   • Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
   • Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
10. Marcella Willemsen · 3 shared papers, 2024–2025 · strength 0.61
    • Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
    • Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
    • Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
11. Michail Doukas · 3 shared papers, 2023–2025 · strength 0.60
    • Paper GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoin… DOI 10.1016/j.xcrm.2024.101557↗
    • Paper Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. PMID 37424830↗
    • Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
12. Fleur van der Sijde · 3 shared papers, 2023–2024 · strength 0.59
    • Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
    • Paper Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pa… DOI 10.3390/cancers15174349↗
    • Paper A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with panc… DOI 10.1016/j.ejca.2022.12.024↗
13. Johanna W. Wilmink · 2 shared papers, 2026 · strength 0.56
    • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
    • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
14. Hassana el Haddaoui · 2 shared papers, 2023–2024 · strength 0.41
    • Paper Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell-Mediated T-Cell Responses. DOI 10.1158/1078-0432.ccr-23-4085↗
    • Paper Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. PMID 37424830↗
15. Eveline E. Vietsch · 2 shared papers, 2024 · strength 0.39
    • Paper FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination th… DOI 10.1016/j.ejca.2023.113440↗
    • Paper The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. DOI 10.1016/j.pan.2024.08.014↗
16. Willem de Koning · 2 shared papers, 2023 · strength 0.38
    • Paper Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pa… DOI 10.3390/cancers15174349↗
    • Paper A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with panc… DOI 10.1016/j.ejca.2022.12.024↗
17. Freek R. van ‘t Land · 2 shared papers, 2024–2025 · strength 0.36
    • Paper REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in meta… DOI 10.1038/s41467-025-66092-1↗
    • Paper The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. DOI 10.1016/j.pan.2024.08.014↗
18. Anne Margarethe Stiggelbout · 1 shared paper, 2026 · strength 0.29
    • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
19. Brigitte C.M. Haberkorn · 1 shared paper, 2026 · strength 0.29
    • Paper The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. DOI 10.1007/s00520-026-10568-3↗
20. Merlijn U.J.E. Graus · 1 shared paper, 2026 · strength 0.27
    • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
21. Jeanin Elise van Hooft · 1 shared paper, 2026 · strength 0.27
    • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
22. Lydia G. van der Geest · 1 shared paper, 2026 · strength 0.27
    • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
23. Ignace H. J. T. de Hingh · 1 shared paper, 2026 · strength 0.27
    • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
24. Thijmen H.T. Broekman · 1 shared paper, 2026 · strength 0.27
    • Paper Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles im… DOI 10.1016/j.ejca.2026.116263↗
25. Leonoor V. Wismans · 1 shared paper, 2025 · strength 0.26
    • Paper Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. DOI 10.1016/j.hpb.2025.02.002↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.